Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section. n/a Confirmed The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Give P values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated Our web collection on statistics for biologists contains articles on many of the points above.
Software and code
Policy information about availability of computer code Data collection
Data analysis
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub The source data underlying Fig. 4b, Fig. 4c, Fig. 5b , Fig. 5c , Supplementary Fig. 3 , Supplementary Fig. 9 , Supplementary Fig. 11 , Supplementary Fig. 12 , Supplementary Fig. 13 , Supplementary Fig. 14, and Supplementary Fig. 15 is available in our Source Data file. An additional dataset that supports findings in this study is available upon reasonable request to the corresponding authors.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size

Data exclusions
Replication Randomization
Blinding
Behavioural & social sciences study design All studies must disclose on these points even when the disclosure is negative.
Study description
Research sample
Sampling strategy
Data collection
Timing Data exclusions
Non-participation
Randomization A goal of the experiments is to demonstrate that our method is capable of obtaining microscopy-grade images of a large number of cells, which cannot be done by conventional microscopes. Therefore, the sample size was determined such that the number of cells is too large to capture all cell images using conventional microscopes and is rationalized by the goal.
Data points with a quantification error (value of 0) were excluded from the populations of the histograms shown in Fig. 4b and Fig. 5b . A data point of the maximum value (46) in the population of E. gracilis -N was excluded for better visibility of the histogram shown in Fig. 5c . Defocused images of particles were excluded from the populations of the histograms shown in Supplementary Fig. 9 . Data points with a value more than 120 were excluded from the histogram shown in Supplementary Fig. 11a for better visibility of the histogram. Data points outside the range of 25 um^2 < x < 40 um^2 were excluded from the population of the histogram shown in Supplementary Fig. 11b as quantification errors. Data points outside the range of 0.65 um^2 < x < 1.6 um^2 were excluded from the population of the histogram shown in Supplementary Fig. 13 as quantification errors. Data points outside the range of 0.65 x 10^-6 um < x < 1.95 um were excluded from the population of the histograms shown in Supplementary Fig. 15 as quantification errors. All the exclusion criteria were determined after reviewing images of particles to confirm that the excluded data points were obvious errors.
The experimental findings were reliably reproduced by at least two independent experiments.
Not applicable because no controlled trials were performed.
Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).
State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.
Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.
Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.
Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.
If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.
State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.
If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.
Ecological, evolutionary & environmental sciences study design
All studies must disclose on these points even when the disclosure is negative. Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.
Describe the data collection procedure, including who recorded the data and how.
Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.
Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.
Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.
Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.
Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).
State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).
Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).
Describe any disturbance caused by the study and how it was minimized.
nature research | reporting summary Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.
Biotinylated anti-Ly6G antibody (RB6-8C5, BioLegend); V500-conjugated Streptavidin (BD Biosciences); Pacific Blue-conjugated anti-CD3# (145-2C11), -CD4 (RM4-5), -CD8! (53-6.7), -B220 (RA3-6B2), -NK1.1 (PK136) antibodies (BioLegend) were used for FACS analysis. Each antibody was used for staining in the final concentration of 1 ug/mL in PBS/2% FBS for 30 min on ice, then washed and resuspended in PBS/2% FBS. Anti-EpCAM antibody (VU-1D9, GeneTex, Irvine, CA), Alexa Flour 488 goat anti-mouse IgG1 (A21121, Invitrogen, Carlsbad, CA), and Hoechst 33342, H3570 (Invitrogen, Carlsbad, CA) were used for imaging of PC-9 cells.
All of the company purchased provides quality certificate for all of the conjugated antibodies certifying that these products have been manufactured and tested in accordance with their specifications. Concerning about reproducibility and validation, BioLegend Cell lines from ATCC have been thoroughly tested and authenticated. ATCC uses morphology, karyotyping, and PCR based approaches to confirm the identity of human cell lines and to rule out both intra-and interspecies contamination. https:// www.atcc.org/CellAuthenticationMatters.aspx RIKEN BRC CELL BANK has been thoroughly tested and authenticated. RIKEN BRC CELL BANK uses morphology, karyotyping, and PCR based approaches to confirm the identity of human cell lines and to rule out both intra-and inter-species contamination. http://cellbank.brc.riken.jp/cell_bank/CellInfo/?cellNo=RCB4455&lang=Ja
The cell lines purchased were negative for mycoplasma contamination, but that was not tested after using them.
No commonly misidentified cell lines were used in the study.
Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).
Indicate where the specimens have been deposited to permit free access by other researchers.
If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.
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Wild animals
Field-collected samples
Ethics oversight
Note that full information on the approval of the study protocol must also be provided in the manuscript.
Human research participants
Policy information about studies involving human research participants
Population characteristics
Recruitment
Ethics oversight
Clinical data Policy information about clinical studies
All manuscripts should comply with the ICMJEguidelines for publication of clinical research and a completedCONSORT checklist must be included with all submissions.
Clinical trial registration
Study protocol
Data collection
Outcomes ChIP-seq
Data deposition
Confirm that both raw and final processed data have been deposited in a public database such as GEO.
Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.
Data access links
May remain private before publication. For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.
Files in database submission
Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.
Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."
Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.
Identify the organization(s) that approved the study protocol.
Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.
Note where the full trial protocol can be accessed OR if not available, explain why.
Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.
Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.
For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.
Provide a list of all files available in the database submission.
Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.
Describe the experimental replicates, specifying number, type and replicate agreement.
Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired-or single-end. Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.
Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.
Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.
The femur bones from C57BL/6 female mice (8 weeks old) were collected by cutting above and below the joints. Bone-marrow cells were washed out of each bone by inserting a needle (26 gauge) with a sterile syringe filled with PBS/2% FBS into one side of the bone. After removing red blood cells by lysis buffer (Sigma-Aldrich), white blood cells were stained with antibodies described above.
FACSAria IIµ (BD Biosciences)
FlowJo (BD Biosciences)
Neutrophils and lymphocytes were sorted based on the gating strategy below and both cells were 100% purity by resorting analysis.
Neutrophils: FSC/SSC, Ly6G+
Lymphocytes: FSC/SSC, Ly6G-CD3e/4/8a/B220/NK1.1+
Indicate task or resting state; event-related or block design.
Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.
State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).
Specify: functional, structural, diffusion, perfusion.
Specify in Tesla
Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.
State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.
